Alta Sciences

FEBRUARY 19, 2025

An oligonucleotide is a short strand of nucleotides, the building blocks of DNA or RNA, used in genetic research and therapy.

Drug Development 52

Drug Development Clinical Pharmacology Immune Response Drugs 52

Drug Target Review

JUNE 6, 2023

Delivery of therapy is being evaluated through injections of DNA and RNA encoding IL-12, viral vectors, and other exploratory platforms designed to bring IL-12 in close proximity to the tumour and avoid excessive IL-12 in systemic circulation. Ultimately, our goal is for this approach to yield an enhanced cancer fighting response.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

The Pharma Data

NOVEMBER 5, 2020

The companies planned to initiate a randomized, multi-center, open-label Phase 2 clinical trial that explores the safety, pharmacokinetics, and antiviral activity of ABI-H0731, RNAi therapeutic AB-729 and an NrtI. AB-729 is an RNA interference (RNAi) therapeutic.

Virus 40

Virus Clinical Trials Therapies Pharmacokinetics 40

Alta Sciences

APRIL 17, 2024

Several viral vectors are being used currently, in addition to non-viral vectors, such as oligonucleotides, naked DNA, and lipoplexes and polyplexes. Oligonucleotide-Based Techniques Most oligonucleotide therapies act through antisense mechanisms and are directed against various RNA species.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

New Drug Approvals

JANUARY 9, 2024

CDK7 also plays a role in transcription and possibly in DNA repair. The trimeric Cak complex CDK7/CyclinH/MATl is also a component of TFIIH, the general transcription/DNA repair factor IIH (Morgan, DO., As a TFIIH subunit, CDK7 phosphorylates the CTD (Carboxy-Terminal-Domain) of the largest subunit of RNA polymerase II (pol II).

Production 62

Production DNA RNA Regulations 62

The Pharma Data

JANUARY 21, 2021

In the ATLAS study, CABENUVA met the primary endpoint for noninferiority (the proportion of participants with plasma HIV-1 RNA ?50 50 copies per milliliter [c/mL] at Week 48), with a comparable number of patients receiving either CABENUVA or their daily current antiretroviral regimen (CAR) having an HIV-1 RNA level ?50

FDA Approval 52

FDA Approval Treatment RNA FDA 52

Codon

APRIL 2, 2023

But now, by studying DNA extracted from microbes in the blood of almost 10,000 healthy people, this paper shows that there is no such thing. Read Transcription factors bind to DNA and control gene expression. Read Switchable hydrophobic pockets in DNA protocells enhance chemical conversion. Nature Microbiology. Meeussen J.V.W.

DNA 52

DNA RNA Engineering Licensing 52